Champignon provides an update on its current trading halt and other corporate matters.
Exploring the companies and themes that make up this emerging and exciting new sector
Psychedelic Drugs: the $16 TRILLION Opportunity?
A 2018 report estimates that mental health issues could cost the global economy $16 trillion between now and 2030. Psychedelic drugs are needed to mitigate those costs.
MagicMed Industries Files First Psychedelic Derivative Patent
MagicMed files with the USPTO with respect to its "broad portfolio of novel psilocybin molecular derivatives, the Psybrary™".
Pharmadrug Inc. Provides Update on Debt Restructuring
PharmaDrug is restructuring approximately $1 million in debt in the form of convertible debentures.
Psychedelics Investing 101: the Drug Approval Process and Drug Patents
Understanding the drug approval process that leads to drug patents and drug licensing is of critical importance for successful investing in psychedelics.
Osoyoos Provides Corporate Update on AI Pharma Acquisition
Osoyoos Cannabis provides additional details on its previously announced acquisition.
Mydecine Adds Biotech Heavy-Hitter To Science Team
Mydecine Innovations Group has added one of the world's pre-eminent biotech scientists to its Scientific Advisory Board.
IntelGenx and Cybin Corp Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film
Cybin Corp is partnering with IntelGenx Corp to produce a new delivery system for pharmaceutical-grade psilocybin.
Mydecine Innovations Group Adds 7-Time Nobel Peace Prize Nominee Dr. M.S Reddy to Its Scientific Advisory Board
Mydecine's new Scientific Advisor holds over 150 U.S. and international patents and will oversee Mydecine's mycology lab.
The Psychedelics Revolution: From ‘War on Drugs’ To Funding Psychedelic Drug Research
The Psychedelics Revolution. One part changing social attitudes. One part medical necessity. One part hard economics.
CannaGlobal, Sansero Life Sciences and Rise Wellness To Merge, Creating a New International Psychedelics Company
Three private companies are merging to create a new entity in the psychedelics space.
Hinterland to Acquire Novamind Ventures Inc
Novamind Ventures Inc. is preparing to go public via amalgamation with unlisted public company, Hinterland Metals Inc.